Form 4: Apellis Pharmaceuticals Acquired by Biogen

Director Gerald Chan reports the disposition of all equity holdings in Apellis Pharmaceuticals following its acquisition by Biogen.

Summary

• Apellis Pharmaceuticals, Inc. has been acquired by Biogen Inc. via a merger agreement dated March 31, 2026.
• The transaction was finalized on May 14, 2026, with Apellis becoming a wholly-owned subsidiary of Biogen.
• Shareholders received $41.00 per share in cash plus one contingent value right (CVR) per share.
• The CVR entitles holders to potential additional payments of up to $4.00 upon the achievement of specific milestones.
• Reporting person Gerald Chan disposed of all direct holdings, including common stock and various stock options, as part of the merger consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing documenting the finalization of a previously announced acquisition.

Positives

• Shareholders received a definitive cash consideration of $41.00 per share.
• The inclusion of a CVR provides potential upside of up to $4.00 per share based on future milestones.

Negatives

• Options with an exercise price equal to or greater than $45.00 were cancelled without consideration.
• The company is no longer a publicly traded entity following the merger.

Risks

• The realization of the $4.00 CVR value is contingent upon the achievement of specific, undisclosed milestones.
• The CVR is non-transferable, limiting liquidity for former shareholders.

Future Outlook

The company has been acquired and is now a wholly-owned subsidiary of Biogen; future operations will be integrated into the parent company's structure.

Management Comments

• The transaction was executed pursuant to the Agreement and Plan of Merger dated March 31, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of large-cap biopharmaceutical companies (Biogen) consolidating mid-cap biotech firms (Apellis) to bolster their pipelines, particularly in specialized therapeutic areas.

Comparison to Industry Standards

• The use of CVRs in this acquisition is consistent with recent industry trends in biotech M&A to bridge valuation gaps between buyers and sellers regarding clinical trial outcomes.

Corporate Governance

Stakeholder Impact

• Shareholders have been cashed out of their positions.
• Employees and creditors are subject to the integration policies of the new parent company, Biogen.

Next Steps

• Integration of Apellis Pharmaceuticals into Biogen operations.
• Monitoring of milestones related to the CVR agreement.

Key Dates

Keywords

Apellis Pharmaceuticals, Biogen, Merger, Acquisition, APLS, Tender Offer, Contingent Value Right, CVR